Back to News
Market Impact: 0.35

1911 Gold secures US$30M credit facility with Auramet to advance True North project

AUMBF
Commodities & Raw MaterialsCredit & Bond MarketsBanking & LiquidityCompany FundamentalsCorporate Guidance & OutlookTrade Policy & Supply ChainRegulation & Legislation
1911 Gold secures US$30M credit facility with Auramet to advance True North project

1911 Gold has secured a US$30 million secured credit facility from Auramet to fund equipment purchases, underground development and a new crushing circuit at the True North/Rice Lake projects; US$15m is available on closing and the remaining US$15m is drawable within 90–180 days. The facility carries a 12% annual interest rate (first tranche interest deferred six months), is secured by first-ranking security on company assets and property mortgages, and includes warrants and fees (payable in cash or shares); Auramet also receives a 100% gold offtake until three years post-close or full repayment. Management says the financing supports the restart plan in the recently released PEA and positions the company for a 2027 production restart; first tranche closing is expected before month-end subject to TSXV approval.

Analysis

Market structure: Auramet and 1911 Gold (AUMBF/AUMB) are the clear beneficiaries — Auramet gains secured physical access to near-term ounces and finance-fee income, while 1911 avoids immediate equity fundraising. Equity holders lose optionality: 100% of production pledged until repayment or three years compresses upside to spot rallies and the warrants/fee-share issuance create near-term overhang. Competitive dynamics favor juniors that secure non-dilutive or credit lines versus those forced to dilute; pricing power for spot gold is unchanged but project-level realized prices for 1911 will be effectively capped by the offtake execution profile. Risk assessment: Key tail risks are project execution failure (underground development or mill upgrades), covenant-triggered acceleration of repayment, and a sharp gold rally that leaves 1911 selling into Auramet at unfavorable netbacks — each could materialize within 6–24 months. Short horizon (days–weeks): TSXV approval and first US$15M drawdown; medium (3–9 months): second tranche drawdown and potential equity/fee issuance; long (12–36 months): technical restart risk targeting 2027. Hidden dependencies include USD funding vs CAD cost base, equipment delivery bottlenecks, and Auramet’s right to seize collateral on covenant breaches. Trade implications: Tactical long exposure to AUMBF (small, idiosyncratic bet) is warranted ahead of tranche closing, but hedge gold-price and sector risk with a short position in GDX or GDXJ to isolate restart optionality. Because of illiquidity and warrant overhang, size positions modestly (1–3% NAV) with strict stops; if second tranche draws, reduce exposure by 50% to avoid dilution risk. Use 6–12 month time horizons — catalysts: TSXV approval (days), drawdown window (90–180 days), construction milestones (quarterly updates). Contrarian angles: Market may be underestimating dilution and downside from the 12%-funded credit with warrants — financing is functionally expensive and offtake-heavy, not a free value-add. Similar junior financings have produced short-term rallies then 30–60% declines on execution misses; price may be overbought post-announcement. Conversely, if Auramet’s balance-sheet and trading flows enable favorable realization vs spot, upside could be asymmetric if restart hits 2027 guidance, so trade small, event-driven stakes rather than buy-and-hold.